A Phase 0, Biomarker Study Evaluating Biomarkers for the Fractalkine System and the Effect of KAND567 on these Biomarkers in in Patients with Lymphoma
Phase of Trial: Phase 0
Latest Information Update: 09 Feb 2019
Price : $35 *
At a glance
- Drugs KAND-567 (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma
- Focus Biomarker; Pharmacodynamics
- 09 Feb 2019 According to a Kancera media release, this study has been carried out by researchers at Karolinska Institutet in collaboration with Kancera.
- 09 Feb 2019 Status changed from recruiting to completed, according to a Kancera media release.
- 09 Feb 2019 Results presented in a Kancera media release.